Citations for
1CELF1, DEK
Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1.
Cifdaloz M, Osterloh L, Graña O, Riveiro-Falkenbach E, Ximénez-Embún P, Muñoz J, Tejedo C, Calvo TG, Karras P, Olmeda D, Miñana B, Gómez-López G, Cañon E, Eyras E, Guo H, Kappes F, Ortiz-Romero PL, Rodríguez-Peralto JL, Megías D, Valcárcel J, Soengas MS.
Nat Commun 8(1):2249. doi: 10.1038/s41467-017-02353-y. 2017
2DEK
DEK proto-oncogene is highly expressed in astrocytic tumors and regulates glioblastoma cell proliferation and apoptosis.
Feng T, Liu Y, Li C, Li Z, Cai H.
Tumour Biol 39(7):1010428317716248. doi: 10.1177/1010428317716248. 2017
3DEK
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sun J, Bi F, Yang Y, Zhang Y, Jin A, Li J, Lin Z.
Oncol Rep 37(2):857-864. doi: 10.3892/or.2016.5302. Epub 2016 Dec 8. 2017
4DEK
Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
Yu L, Huang X, Zhang W, Zhao H, Wu G, Lv F, Shi L, Teng Y.
Oncotarget 7(18):26844-55. doi: 10.18632/oncotarget.8565. 2016
5DEK, NUP214
The DEK oncoprotein and its emerging roles in gene regulation.
Sandén C, Gullberg U.
Leukemia eukemia. 2015 Mar 13. doi: 10.1038/leu.2015.72. [Epub ahead of print] 2015
6DEK, KLF1
The DEK Oncoprotein Is a Critical Component of the EKLF/KLF1 Enhancer in Erythroid Cells.
Lohmann F, Dangeti M, Soni S, Chen X, Planutis A, Baron MH, Choi K, Bieker JJ.
Mol Cell Biol 35(21):3726-38. doi: 10.1128/MCB.00382-15. Epub 2015 Aug 24. 2015
7DEK
The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.
Deutzmann A, Ganz M, Schönenberger F, Vervoorts J, Kappes F, Ferrando-May E.
Oncogene 34(32):4270-7. doi: 10.1038/onc.2014.346. Epub 2014 Oct 27. 2015
8DEK
The DEK oncoprotein binds to highly and ubiquitously expressed genes with a dual role in their transcriptional regulation.
Sandén C, Järvstråt L, Lennartsson A, Brattås PL, Nilsson B, Gullberg U.
Mol Cancer 13:215. doi: 10.1186/1476-4598-13-215. 2014
9DEK, TERT
Chromatin redistribution of the DEK oncoprotein represses hTERT transcription in leukemias.
Karam M, Thenoz M, Capraro V, Robin JP, Pinatel C, Lancon A, Galia P, Sibon D, Thomas X, Ducastelle-Lepretre S, Nicolini F, El-Hamri M, Chelghoun Y, Wattel E, Mortreux F.
Neoplasia 16(1):21-30. 2014
10DEK
Intercellular trafficking of the nuclear oncoprotein DEK.
Saha AK, Kappes F, Mundade A, Deutzmann A, Rosmarin DM, Legendre M, Chatain N, Al-Obaidi Z, Adams BS, Ploegh HL, Ferrando-May E, Mor-Vaknin N, Markovitz DM.
Proc Natl Acad Sci U S A 110(17):6847-52. doi: 10.1073/pnas.1220751110. Epub 2013 Apr 8. 2013
11CEBPA, DEK
C/EBPα and DEK coordinately regulate myeloid differentiation.
Koleva RI, Ficarro SB, Radomska HS, Carrasco-Alfonso MJ, Alberta JA, Webber JT, Luckey CJ, Marcucci G, Tenen DG, Marto JA.
Blood 119(21):4878-88. doi: 10.1182/blood-2011-10-383083. Epub 2012 Apr 3. 2012
12DEK
DEK regulates hematopoietic stem engraftment and progenitor cell proliferation.
Broxmeyer HE, Kappes F, Mor-Vaknin N, Legendre M, Kinzfogl J, Cooper S, Hangoc G, Markovitz DM.
Stem Cells Dev 21(9):1449-54. doi: 10.1089/scd.2011.0451. Epub 2011 Oct 27. 2012
13DEK
The human DEK oncogene regulates DNA damage response signaling and repair.
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmüller L, Wells SI.
Nucleic Acids Res 39(17):7465-76. doi: 10.1093/nar/gkr454. Epub 2011 Jun 7. 2011
14DEK, NUP214
A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor.
Sawatsubashi S, Murata T, Lim J, Fujiki R, Ito S, Suzuki E, Tanabe M, Zhao Y, Kimura S, Fujiyama S, Ueda T, Umetsu D, Ito T, Takeyama K, Kato S.
Genes Dev 24(2):159-70. Epub 2009 Dec 29.PMID: 20040570 2010
15DEK
The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells.
Secchiero P, Voltan R, di Iasio MG, Melloni E, Tiribelli M, Zauli G.
Clin Cancer Res 16(6):1824-33. Epub 2010 Mar 9.PMID: 20215548 2010
16DEK
Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S, Xuan Y, Liu S, Zhang M, Jin D, Jin R, Lin Z.
Pathol Int 59(7):443-7.PMID: 19563407 2009
17DEK
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI.
Cancer Res 69(5):1792-9. Epub 2009 Feb 17.PMID: 19223548 2009
18DEK
DEK proto-oncogene expression interferes with the normal epithelial differentiation program.
Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI.
Am J Pathol 174(1):71-81. Epub 2008 Nov 26.PMID: 19036808 2009
19NUP214, DEK
Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
Ageberg M, Drott K, Olofsson T, Gullberg U, Lindmark A.
Genes Chromosomes Cancer 47(4):276-87. 2008
20DEK
DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F, Fahrer J, Khodadoust MS, Tabbert A, Strasser C, Mor-Vaknin N, Moreno-Villanueva M, Bürkle A, Markovitz DM, Ferrando-May E.
Mol Cell Biol 28(10):3245-57. Epub 2008 Mar 10.PMID: 18332104 2008
21DEK,PARP1,SET
SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery.
Gamble MJ, Fisher RP.
Nat Struct Mol Biol 14(6):548-55. Epub 2007 May 27. 2007
22DEK
The involvement of cellular proliferation status in the expression of the human proto-oncogene DEK.
Ageberg M, Gullberg U, Lindmark A.
Haematologica 91(2):268-9. 2006
23DEK, EP300, KAT2B
Regulation of histone acetyltransferase activity of p300 and PCAF by proto-oncogene protein DEK.
Ko SI, Lee IS, Kim JY, Kim SM, Kim DW, Lee KS, Woo KM, Baek JH, Choo JK, Seo SB.
FEBS Lett 580(13):3217-22. Epub 2006 May 4. 2006
24DEK
DEK Expression is controlled by E2F and deregulated in diverse tumor types.
Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Muller H.
Cell Cycle 5(11):1202-7. Epub 2006 Jun 1. 2006
25DEK
Intron removal requires proofreading of U2AF/3' splice site recognition by DEK.
Soares LM, Zanier K, Mackereth C, Sattler M, Valcarcel J.
Science 312(5782):1961-5. 2006
26DEK
The SAF-box domain of chromatin protein DEK.
Bohm F, Kappes F, Scholten I, Richter N, Matsuo H, Knippers R, Waldmann T.
Nucleic Acids Res 33(3):1101-10. Print 2005. 2005
27DEK
Distribution of the chromatin protein DEK distinguishes active and inactive CD21/CR2 gene in pre- and mature B lymphocytes.
Hu HG, Illges H, Gruss C, Knippers R.
Int Immunol 17(6):789-96. Epub 2005 May 20. 2005
28DEK
Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma.
Grasemann C, Gratias S, Stephan H, Schuler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, Lohmann DR.
Oncogene 24(42):6441-9. 2005
29DEK
Functional domains of the ubiquitous chromatin protein DEK.
Kappes F, Scholten I, Richter N, Gruss C, Waldmann T.
Mol Cell Biol 24(13):6000-10. 2004
30DEK
Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK.
Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C.
Mol Cell Biol 24(13):6011-20. 2004
31DEK
Transcriptional activation by AP-2alpha is modulated by the oncogene DEK.
Campillos M, Garcia MA, Valdivieso F, Vazquez J.
Nucleic Acids Res 31(5):1571-5. 2003
32DEK, IGFBP1, LGALS4, LY6E, UGT2B4
Identification and characterization of genes associated with human hepatocellular carcinogenesis.
Kondoh N, Wakatsuki T, Ryo A, Hada A, Aihara T, Horiuchi S, Goseki N, Matsubara O, Takenaka K, Shichita M, Tanaka K, Shuda M, Yamamoto M.
Cancer Res 59(19):4990-6. 1999
33DEK
Establishment of a novel human myeloid leukaemia cell line (FKH-1) with t(6;9)(p23;q34) and the expression of dek-can chimaeric transcript.
Hamaguchi H, et al.
Br J Haematol 102 : 1249-1256. 1998
34DEK
DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.
Fu GK, Grosveld G, Markovitz DM.
Proc Natl Acad Sci U S A 94(5):1811-5. 1997
35EDN1, GMPR, SCA1, DEK
An integrated map of human chromosome 6p23.
Olavesen MG, et al.
Genome Res 5 : 342-358. 1995
36DEK, NUP214, CAN
The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.
von Lindern M, et al.
Mol Cell Biol 12 : 1687-1697. 1992
37NUP214, DEK, CAN
The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features.
Soekarman D, et al.
Blood 79 : 2990-2997. 1992
38NUP214, DEK, CAN
Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia.
Von Lindern M, et al.
Genes Chromosomes Cancer 5 : 227-234. 1992
39NUP214, D9S46, DEK,CAN
The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34.
von Lindern M, et al.
Mol Cell Biol 10 : 4016-4026. 1990